Skip to main content

Advertisement

SpringerLink
Log in

Current challenges in the management of invasive fungal infections

  • Review Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

The incidence of invasive fungal infections (IFIs) has increased over the past two decades, as the populations of patients at risk have continued to rise. Early and accurate diagnosis and the subsequent usage of appropriate antifungal therapy are difficult, which leads to a high mortality rate in patients with IFI. Along with the widespread use of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non-albicans Candida, Non-fumigatus Aspergillus, and molds other than Aspergillus have become more common pathogens causing invasive diseases, and most of these emerging fungi are resistant to or less susceptible than others to standard antifungal agents. Therefore, invasive infections due to these previously rare fungi are more difficult to treat. Advances in more potent and less toxic antifungal agents, such as second-generation triazoles and echinocandins, may potentially improve the outcomes of these infections. Recent advances in detecting fungal cell-wall components and genomic DNA also allow earlier diagnosis. This article reviews the changing spectrum of invasive fungal infections and the introduction of recent advances in diagnostic tools and antifungal agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546–1554.

    PubMed  Google Scholar 

  2. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2004;17:511–515.

    Google Scholar 

  3. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43(Suppl 1):S3–S14.

    CAS  Google Scholar 

  4. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359–366.

    PubMed  CAS  Google Scholar 

  5. Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2007 [Epub ahead of print]

  6. Hsueh PR, Teng LJ, Yang PC, Ho SW, Luh KT. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist 2002;8:311–319.

    PubMed  CAS  Google Scholar 

  7. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857–863.

    PubMed  Google Scholar 

  8. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685–702.

    PubMed  Google Scholar 

  9. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634–643.

    PubMed  Google Scholar 

  10. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519–1527.

    PubMed  Google Scholar 

  11. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005;41:521–526.

    PubMed  Google Scholar 

  12. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995;8:462–478.

    PubMed  CAS  Google Scholar 

  13. Clark TA, Slavinski SA, Morgan J, Arthington-Skaggs BA, Brandt ME, Webb RM, et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004;42:4468–4472.

    PubMed  CAS  Google Scholar 

  14. Kuhn DM, Mikherjee PK, Clark TA, Pujol C, Chandra J, Hajjeh RA, et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004;10:1074–1081.

    PubMed  Google Scholar 

  15. Sarvikivi E, Lyytikainen O, Soll DR, Pujol C, Pfaller MA, Richardson M, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005;43:2729–2735.

    PubMed  CAS  Google Scholar 

  16. Kauffman CA. Fungal infections in older adults. Clin Infect Dis 2001;33:550–555.

    PubMed  CAS  Google Scholar 

  17. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002;40:3551–3557.

    PubMed  CAS  Google Scholar 

  18. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GB, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J Clin Microbiol 2002;40:1298–1302.

    PubMed  CAS  Google Scholar 

  19. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002:40:852–856.

    PubMed  CAS  Google Scholar 

  20. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005;41:975–981.

    PubMed  Google Scholar 

  21. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253–258.

    PubMed  CAS  Google Scholar 

  22. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000;19:319–324.

    PubMed  CAS  Google Scholar 

  23. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122–1128.

    PubMed  CAS  Google Scholar 

  24. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309–316.

    PubMed  CAS  Google Scholar 

  25. Baran J Jr, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis 2001;33:137–139.

    PubMed  Google Scholar 

  26. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001;33:1676–1681.

    PubMed  CAS  Google Scholar 

  27. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115–125.

    PubMed  CAS  Google Scholar 

  28. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of the worldwide susceptibility of Candida and other yeasts species to fluconazole and voriconazole using standardized disk diffusion testing. J Clin Microbiol 2005;43:5848–5859.

    PubMed  CAS  Google Scholar 

  29. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 2002;35:627–630.

    PubMed  CAS  Google Scholar 

  30. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309–321.

    CAS  Google Scholar 

  31. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002;50:56–65.

    PubMed  CAS  Google Scholar 

  32. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. International Fungal Surveillance Participant Group. Clin Microbiol Infect 2004;10(Suppl 1):11–23.

    PubMed  CAS  Google Scholar 

  33. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149–3154.

    PubMed  CAS  Google Scholar 

  34. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201–205.

    PubMed  CAS  Google Scholar 

  35. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3000 clinical isolates. J Clin Microbiol 2004;42:3117–3119.

    PubMed  CAS  Google Scholar 

  36. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723–1727.

    PubMed  CAS  Google Scholar 

  37. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909–917.

    PubMed  Google Scholar 

  38. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250–260.

    CAS  Google Scholar 

  39. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2768–2776.

    PubMed  CAS  Google Scholar 

  40. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013–1025.

    PubMed  Google Scholar 

  41. Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment — rethinking our approach to prevention. Clin Infect Dis 2001;33:1549–1552.

    PubMed  CAS  Google Scholar 

  42. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623–3626.

    PubMed  CAS  Google Scholar 

  43. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillosis terreus: 12-year experience and review of the literature. Clin Infect Dis 1998;26:1092–1097.

    PubMed  CAS  Google Scholar 

  44. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004;39:192–198.

    PubMed  Google Scholar 

  45. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Mycoses Study Group. Clin Infect Dis 2001;33:1824–1833.

    PubMed  CAS  Google Scholar 

  46. Baddley JW, Park B, Marr KA, Andes DR, Kontoyiannis DP, Hadley S, et al. Factors influencing mortality in transplant recipients with invasive aspergillosis (abstract 673). In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: The University of Chicago Press; 2004. p. 174.

    Google Scholar 

  47. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Bellequic C, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006;43:577–584.

    PubMed  CAS  Google Scholar 

  48. Lai CC, Liaw SJ, Lee LN, Hsiao CH, Yu CJ, Hsueh PR. Invasive aspergillosis: high incidence of disseminated intravascular coagulation in fatal cases. J Microbiol Immunol Infect 2007;40:141–147.

    PubMed  Google Scholar 

  49. Roden MM, Zaoutis T, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634–653.

    PubMed  Google Scholar 

  50. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002;16:895–914.

    PubMed  Google Scholar 

  51. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556–569.

    PubMed  CAS  Google Scholar 

  52. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126–133.

    PubMed  CAS  Google Scholar 

  53. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004;38:1237–1242.

    PubMed  Google Scholar 

  54. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003;98:315–319.

    PubMed  Google Scholar 

  55. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007;20:695–704.

    PubMed  CAS  Google Scholar 

  56. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002;15:465–484.

    PubMed  Google Scholar 

  57. Ulusakarya A, Chachaty E, Vantelon JM, Youssef A, Tancrede C, Pico JL, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000;1:111–116.

    PubMed  CAS  Google Scholar 

  58. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349–357.

    PubMed  CAS  Google Scholar 

  59. Shao PL, Huang LM, Hsueh PR. Invasive fungal infection-laboratory diagnosis and antifungal treatment. J Microbiol Immunol Infect 2006;39:178–188.

    PubMed  CAS  Google Scholar 

  60. Lai CC, Hsu HL, Lee LN, Hsueh PR. Assessment of Platelia Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis. J Microbiol Immunol Infect 2007;40:148–153.

    PubMed  Google Scholar 

  61. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199–205.

    PubMed  CAS  Google Scholar 

  62. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013–1025.

    PubMed  Google Scholar 

  63. Ostrosky-Zeichner L, Alexander BD, 9 Kett DH, Vazque J, Paappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1−>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654–659.

    PubMed  CAS  Google Scholar 

  64. Buchheidt D, Hummel M, Schleiermacher D, Spiess B, Schwerdtfeger R, Cornely OA, et al. Prospective clinical evaluation of a Light Cycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004;125:196–202.

    PubMed  CAS  Google Scholar 

  65. Spiess B, Buchheidt D, Baust C, Skladny H, Seifarth W, Zeilfelder U, et al. Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J Clin Microbiol 2003;41:1811–1818.

    PubMed  CAS  Google Scholar 

  66. Costa C, Costa JM, Desterke C, Botterel F, Cordonnier C, Bretagne S. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002;40:2224–2227.

    PubMed  CAS  Google Scholar 

  67. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000;30:653–657.

    PubMed  CAS  Google Scholar 

  68. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:689–693.

    Google Scholar 

  69. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacol 1998;35:461–473.

    CAS  Google Scholar 

  70. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018–3021.

    PubMed  CAS  Google Scholar 

  71. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343–500.

    PubMed  CAS  Google Scholar 

  72. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997–2020.

    PubMed  CAS  Google Scholar 

  73. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630–637.

    PubMed  CAS  Google Scholar 

  74. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546–2553.

    PubMed  CAS  Google Scholar 

  75. Leveque D, Niviox Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274–284.

    PubMed  CAS  Google Scholar 

  76. Keating GM. Posaconazole. Drugs 2005;65:1553–1567.

    PubMed  CAS  Google Scholar 

  77. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration of posaconazole in healthy subjects. Antimicrob Agents Chemother 2004;48:3543–3551.

    PubMed  CAS  Google Scholar 

  78. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122–1131.

    PubMed  CAS  Google Scholar 

  79. Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Microbiol Infect Dis 2004;23:256–270.

    CAS  Google Scholar 

  80. Munayyer HK, Mann PA, Chau AS, Yarosh-Tomaine T, Greene JR, Hare RS, et al. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004;48:3690–3696.

    PubMed  CAS  Google Scholar 

  81. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002;46:1144–1146.

    PubMed  CAS  Google Scholar 

  82. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950–2956.

    PubMed  CAS  Google Scholar 

  83. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-104xxx496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996;40:1948–1949.

    PubMed  CAS  Google Scholar 

  84. Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998;31:297–300.

    PubMed  CAS  Google Scholar 

  85. Barchiesi F, Arzeni D, Fothergill AW, Di Francesco LF, Caselli F, Rinaldi MG, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000;44:226–229.

    PubMed  CAS  Google Scholar 

  86. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996;40:1910–1913.

    PubMed  CAS  Google Scholar 

  87. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43:2163–2167.

    PubMed  CAS  Google Scholar 

  88. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12052 fungal isolates: review of the literature. Rev Iberoam Micol 2003;20:121–136.

    PubMed  Google Scholar 

  89. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 2003;41:5233–5255.

    PubMed  CAS  Google Scholar 

  90. Oakley KL, Moore CB, Denning DW. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998;42:91–94.

    PubMed  CAS  Google Scholar 

  91. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar DH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH-56592). J Antimicrob Chemother 2000;46:229–234.

    PubMed  CAS  Google Scholar 

  92. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998;17:573–575.

    PubMed  CAS  Google Scholar 

  93. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001;45:2151–2153.

    PubMed  CAS  Google Scholar 

  94. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002;34:1415–1417.

    PubMed  Google Scholar 

  95. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobiol Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032–1037.

    PubMed  CAS  Google Scholar 

  96. Gonzalez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005;43:281–284.

    PubMed  CAS  Google Scholar 

  97. Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi M, Loebenberg D, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002;46:1352–1356.

    PubMed  CAS  Google Scholar 

  98. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000;44:1734–1736.

    PubMed  CAS  Google Scholar 

  99. Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriquez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B flucytosin, itraconazole, and voriconazole. J Antimicrob Chemother 2001;48:919–921.

    PubMed  CAS  Google Scholar 

  100. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003;51:45–52.

    PubMed  CAS  Google Scholar 

  101. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581–1582.

    PubMed  CAS  Google Scholar 

  102. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.

    PubMed  CAS  Google Scholar 

  103. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563–571.

    PubMed  CAS  Google Scholar 

  104. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–234.

    PubMed  CAS  Google Scholar 

  105. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447–1454.

    PubMed  CAS  Google Scholar 

  106. Ostrosky-Zeichner L, Oude-Lashof AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:651–655.

    PubMed  CAS  Google Scholar 

  107. Garbino J, Uckay I, Rohner P, Lew D, van Delden C. Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature. Transplant Int 2005;18:613–618.

    Google Scholar 

  108. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003;37:311–313.

    PubMed  Google Scholar 

  109. Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006;43:e39–e41.

    PubMed  Google Scholar 

  110. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2–12.

    PubMed  CAS  Google Scholar 

  111. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–359.

    PubMed  CAS  Google Scholar 

  112. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335–347.

    PubMed  CAS  Google Scholar 

  113. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630–637.

    PubMed  CAS  Google Scholar 

  114. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001;61:1545–1548.

    Google Scholar 

  115. Denning DW. Echinocandin antifugal drugs. Lancet 2003;362:1142–1151.

    PubMed  CAS  Google Scholar 

  116. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006:42:1171–1178.

    PubMed  CAS  Google Scholar 

  117. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, et al. Single-and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46:739–745.

    PubMed  CAS  Google Scholar 

  118. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006:43:215–222.

    PubMed  Google Scholar 

  119. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, et al. Phase 2, randomized, dose ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48:2021–2024.

    PubMed  CAS  Google Scholar 

  120. Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000;28:1274–1278.

    PubMed  CAS  Google Scholar 

  121. Caspofungin acetate. FDA Advisory Committee meeting background. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf (accessed Jan 28, 2007)

  122. Keating GM, Figgitt DP. Caspofungin: a review of its use in oesophageal candidasis, invasive candidiasis and invasive aspergillosis. Drugs 2003;63:2235–2263.

    PubMed  CAS  Google Scholar 

  123. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of andiulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590–598.

    PubMed  CAS  Google Scholar 

  124. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006:50:2892–2894.

    PubMed  CAS  Google Scholar 

  125. Hakii M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006:50:2522–2524.

    Google Scholar 

  126. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006;42:938–944.

    PubMed  CAS  Google Scholar 

  127. Moudgal V, Little T, Boikov D, Vanquez JA. Multiechinocandinand multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005:49:767–769.

    PubMed  CAS  Google Scholar 

  128. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005:49:3264–3273.

    PubMed  CAS  Google Scholar 

  129. Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus species. Antimicrob Agents Chemother 1998;42:2726–2730.

    PubMed  CAS  Google Scholar 

  130. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57–62.

    Article  PubMed  CAS  Google Scholar 

  131. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002;46:245–247.

    PubMed  CAS  Google Scholar 

  132. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000;53:1175–1181.

    CAS  Google Scholar 

  133. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020–2029.

    PubMed  CAS  Google Scholar 

  134. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391–1402.

    PubMed  CAS  Google Scholar 

  135. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563–1571.

    PubMed  CAS  Google Scholar 

  136. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337–349.

    PubMed  Google Scholar 

  137. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized double blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221–1228.

    PubMed  CAS  Google Scholar 

  138. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infection. Clin Microbiol Rev 2005;18:163–194.

    PubMed  CAS  Google Scholar 

  139. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292–299.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Yi-Min Hospital, Taipei, Taiwan, China

    Chih-Cheng Lai

  2. Department of Intensive Care Medicine, Chi-Mei Medical Center, Yungkang, Tainan, Taiwan, China

    Che-Kim Tan

  3. Far Eastern Memorial Hospital, Taipei County, Taiwan, China

    Yu-Tsung Huang

  4. Department of Pediatrics and Divisions of Clinical Microbiology and Infectious Diseases, National Taiwan University Hospital, Taipei, Taiwan, China

    Pei-Lan Shao

  5. Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No 7, Chung-Shan South Road, Taipei, 100, Taiwan, China

    Po-Ren Hsueh

Authors
  1. Chih-Cheng Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Che-Kim Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-Tsung Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pei-Lan Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Po-Ren Hsueh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Po-Ren Hsueh.

About this article

Cite this article

Lai, CC., Tan, CK., Huang, YT. et al. Current challenges in the management of invasive fungal infections. J Infect Chemother 14, 77–85 (2008). https://doi.org/10.1007/s10156-007-0595-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-007-0595-7

Key words

Search

Navigation